Testing effectiveness (Phase 2)Study completedNCT00136539What this trial is testingNeoadjuvant Therapy With Herceptin and Taxol for Breast CancerWho this might be right forBreast Cancer Harold J. Burstein, MD, PhD 41
Testing effectiveness (Phase 2)Looking for participantsNCT07492394What this trial is testingDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast CancerWho this might be right forBreast Cancer Hebei Medical University Fourth Hospital 60
Not applicableNot Yet RecruitingNCT07098507What this trial is testingDe-escalation in Axillary Surgery for Early-stage Breast CancerWho this might be right forOmitting Sentinel Lymph Node Biopsy in Early-stage Breast Cancer Clinical Hospital Center Rijeka 620
Not applicableUnknownNCT05491057What this trial is testingTreatment Patterns of Neratinib in HER2+ EBC in ChinaWho this might be right forBreast Cancer Pierre Fabre Medicament 500
Testing effectiveness (Phase 2)Study completedNCT00436566What this trial is testingDoxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By SurgeryWho this might be right forBreast CancerCardiac Toxicity Mayo Clinic 122
Testing effectiveness (Phase 2)Looking for participantsNCT05306041What this trial is testingNeoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerWho this might be right forHER2-positive Breast Cancer GBG Forschungs GmbH 170
Not applicableUnknownNCT05656079What this trial is testingTo Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical StudyWho this might be right forBreast Cancer Shanghai Pudong Hospital 204
Testing effectiveness (Phase 2)UnknownNCT03906669What this trial is testingA Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.Who this might be right forEarly-stage Breast CancerHormone Receptor Positive Tumor St Vincent's Hospital 200
Large-scale testing (Phase 3)Looking for participantsNCT07541079What this trial is testingA Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)Who this might be right forEarly Breast Cancer Genentech, Inc. 300
Early research (Phase 1)Not Yet RecruitingNCT07601620What this trial is testingEvaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast CancerWho this might be right forHER2 + Breast Cancer Shanghai Henlius Biotech 258
Very early researchActive Not RecruitingNCT05333874What this trial is testingCIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early StageWho this might be right forBreast Cancer, Early-Onset Rutgers, The State University of New Jersey 34
Early research (Phase 1)Study completedNCT02418624What this trial is testingPhase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced CancerWho this might be right forBreast CancerOvarian CancerAdvanced Cancer The Netherlands Cancer Institute 25
Testing effectiveness (Phase 2)Looking for participantsNCT06927180What this trial is testingSHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BCWho this might be right forBreast Cancer Early Stage Breast Cancer (Stage 1-3) Henan Cancer Hospital 180
Large-scale testing (Phase 3)Looking for participantsNCT05891093What this trial is testingEfficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)Who this might be right forBreast Cancer Fudan University 766
Testing effectiveness (Phase 2)Looking for participantsNCT07407920What this trial is testingPh2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialWho this might be right forAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage HER2-Positive Breast Carcinoma+1 more M.D. Anderson Cancer Center 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07101159What this trial is testingDalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsWho this might be right forEarly Breast CancerAdjuvant TherapyHormone Receptor Positive / HER2-negative Breast Cancer Fujian Cancer Hospital 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07109284What this trial is testingSKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast CancerWho this might be right forER+HER2- Breast Cancer West China Hospital 55
Large-scale testing (Phase 3)Not Yet RecruitingNCT07213206What this trial is testingCDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast CancerWho this might be right forBreast Cancer Fudan University 1,500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07307287What this trial is testingSHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II StudyWho this might be right forSHR-A1811HER2-Postive Breast CancerHR+ Breast Cancer+2 more Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03735966What this trial is testingNeoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.Who this might be right forHER2 Positive Breast Cancer Henan Cancer Hospital 75